Sample Prescription for CombiPatch 0.05mg-0.14mg/24hr
For postmenopausal women with an intact uterus requiring hormone replacement therapy, prescribe CombiPatch (estradiol 0.05mg/norethindrone acetate 0.14mg per day) as one patch applied twice weekly in a continuous combined regimen.
Prescription Format
Rx: CombiPatch 0.05mg-0.14mg/24hr transdermal patch
- Sig: Apply one patch to clean, dry skin on lower abdomen or buttocks. Change patch twice weekly (every 3-4 days). Rotate application sites.
- Dispense: #8 patches (1 month supply)
- Refills: As appropriate for ongoing therapy
Application Instructions
- Apply patch to lower abdomen or buttocks on clean, dry, hairless skin
- Change twice weekly on the same two days each week (e.g., Sunday and Wednesday)
- Rotate application sites with at least 1 week between using the same site
- Press firmly for 10 seconds to ensure adhesion
- Avoid waistline where clothing may rub the patch off
Clinical Context
This formulation combines estradiol with norethindrone acetate in a continuous combined regimen, which is appropriate for postmenopausal women with an intact uterus 1. The transdermal route avoids first-pass hepatic metabolism, providing more stable hormone levels and potentially reducing cardiovascular and thromboembolic risks compared to oral formulations 1.
Key Prescribing Considerations:
- Endometrial protection: The 0.14mg norethindrone acetate dose provides adequate progestogen coverage to prevent endometrial hyperplasia when used continuously 1
- Continuous vs. sequential: This continuous combined patch (used without interruption) typically results in amenorrhea in most women after several months, which many patients prefer 2, 3
- Duration: Continue therapy at least until age 51 (average age of natural menopause) or longer based on symptom control and risk-benefit assessment 4
Common Pitfalls to Avoid:
- Do not prescribe sequential regimens (estrogen-only followed by combined patches) unless the patient specifically desires withdrawal bleeding 1
- Monitor for patch detachment: If patch detaches for <48 hours, reapply or replace immediately; if ≥48 hours, follow backup contraception guidelines if patient is perimenopausal 5
- Application site reactions are the most common adverse effect—counsel patients to rotate sites and report persistent irritation 6, 7
Patient Counseling Points:
- Vasomotor symptoms typically improve within 1-2 weeks; other symptoms may take longer 1
- Most women become amenorrheic after 6-12 months of continuous use 2
- Report any unusual vaginal bleeding, breast lumps, severe headaches, or leg pain/swelling immediately
- Patch may be less effective in women >90 kg body weight